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Dr Reddydoi:10.1016/j.jtcvs.2004.06.036Background: Cancer cells frequently exhibit resistance to the cytotoxic effect of
tumor necrosis factor–related apoptosis-inducing ligand (TRAIL). Pretreatment of
TRAIL-resistant cells with cisplatin sensitizes them to this ligand. Cisplatin also has
been shown to enhance adenoviral transgene expression.
Objective: This study aims to evaluate the ability of cisplatin to enhance the
expression and the cytotoxic effect of the tumor-specific adenoviral vector Ad/
gTRAIL, which expresses a green fluorescent protein–TRAIL fusion protein.
Methods: Cultured cancer cells and normal human cells were infected with Ad/
gTRAIL with or without cisplatin pretreatment. Adenoviral transgene expression
was determined by using flow cytometry to measure green fluorescent protein
fluorescence. Cytotoxicity was measured by using thiazolyl blue tetrazolium bro-
mide assays and an apoptosis enzyme-linked immunosorbent assay kit.
Results: Green fluorescent protein–TRAIL fusion protein expression was signifi-
cantly enhanced by cisplatin pretreatment in cancer cells. Cisplatin treatment before
Ad/gTRAIL infection resulted in a 2- to 12-fold increase in green fluorescent protein
fluorescence intensity across cancer lines. Although Ad/gTRAIL induced mild
cytotoxicity in all cancer lines (inhibitory concentration of 50% values of 500
pfu/cell), pretreatment with cisplatin resulted in a dose-dependent enhancement of
Ad/gTRAIL-mediated cytotoxicity, as indicated by the drastic reduction of inhibi-
tory concentration of 50% values to 4 to 42 pfu/cell in all cell lines. There was no
cytotoxicity noted in normal cells treated with both cisplatin and Ad/gTRAIL.
Conclusion: Cisplatin pretreatment enhances Ad/gTRAIL cytotoxicity in malignant
cells while not affecting normal cells. The mechanisms underlying this effect might
include both enhancement of the susceptibility of cisplatin-treated cells to TRAIL
and cisplatin-mediated enhancement of TRAIL expression in Ad/gTRAIL infected
cells. These findings provide a rationale for development of Ad/gTRAIL-based
therapy for thoracic malignancies.
Primary cancers of the thoracic cavity, those that originate from thelung, the esophagus, and the pleura, remain the most common and,unfortunately, the most resistant to standard multimodality combina-tions of surgical intervention, chemotherapy, and radiotherapy. Ag-gressive systemic therapy with cytotoxic agents might provide sub-jective responses, yet patients are plagued with severe side effects.
The mechanism of resistance to chemotherapy or radiotherapy in malignant cells is
multifactorial and incompletely understood. Better appreciation of the molecular
basis of tumorigenesis, particularly signal transduction pathways that govern cell
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development of molecular therapeutic approaches that se-
lectively target cancer cells and not normal cells.
Receptor-mediated apoptosis-inducing pathways con-
trolled by members of the tumor necrosis factor (TNF)
superfamily, particularly those controlled by TNF-related
apoptosis-inducing ligand (TRAIL), attract significant at-
tention and are currently undergoing preclinical develop-
ment.1 Binding of TRAIL to its cognate receptors, DR4 or
DR5, initiates a well-defined cascade of caspase activation,
leading to a rapid and profound induction of apoptosis in
susceptible malignant cells while sparing normal cells.2 The
gene encoding human TRAIL has been cloned, and the
soluble recombinant protein has been shown to mediate
potent antitumor activity both in vitro3 and in in vivo
preclinical animal experiments.4 It is well documented that
cytotoxic chemotherapeutic agents synergistically interact
with TRAIL to induce apoptosis, even in TRAIL-resistant
cancer cells.5,6 We have shown the DNA-damaging agent
cisplatin to be a potent chemoenhancer of soluble Fas
ligand–mediated apoptosis7 and Apo2L/TRAIL-mediated
apoptosis.8 in various thoracic malignancies. Even with
these promising results, there has been concern regarding
hepatotoxicity with systemic administration.9
Adenovirus is a commonly used vector to deliver therapeu-
tic genes to eukaryotes. It is limited by its tropism for hepato-
cytes and its indiscriminate infectivity in both cancer cells and
normal cells.10 Adenovirus expressing the membrane-bound
green fluorescent protein (GFP)–TRAIL fusion protein under
the control of the human telomerase reverse transcriptase
(hTERT) promoter (Ad/gTRAIL) has been shown to be selec-
tively active in transformed, but not normal, cells because
hTERT is overexpressed in up to 90% of cancer cells. This
vector has also been evaluated in normal human hepatocytes
and shown to initiate minimal TRAIL expression, and it has no
cytotoxicity.11 These features make such a recombinant ade-
novirus an attractive vector for cancer gene therapy. Moreover,
it has been demonstrated that pretreating cancer cells with
subtherapeutic doses of cisplatin would result in significant
enhancement of adenovirally mediated transgene expression
and function of therapeutic genes.12
In this study we evaluated the enhanced transgene ex-
pression and the cytotoxic effect of Ad/gTRAIL after cis-
platin treatment in a panel of cultured cancer cells derived
from cancers of the lung (non–small cell lung cancer
[NSCLC]), the esophagus (esophageal cancer [EsC]), and
the pleura (malignant pleural mesothelioma [MPM]). We
also tested the safety of these agents in normal human cells.
Combining Ad/gTRAIL with cisplatin would exploit 2 po-
tentially beneficial effects of cisplatin, the enhancement of
adenoviral transgene expression in effector cells and the
potentiation of a TRAIL effect on target cells, and this
might result in a synergistic therapeutic effect.
884 The Journal of Thoracic and Cardiovascular Surgery ● DeceMaterials and Methods
Cells and Reagents
Cultured NSCLC cells (H322), EsC cells (TE2 and TE12), and
MPM cells (H513, H2373, and H28) were maintained in RPMI-
1640 medium supplemented with glutamine (1 mmol/L), strepto-
mycin (100 mg/mL), penicillin (100 U/mL), and fetal calf serum
(5% vol/vol; complete media). Normal human fibroblasts, human
umbilical vein endothelial cells, and normal human keratinocytes
were purchased from Clonetics Corp (Walkerville, Md) and cul-
tured with appropriate media as per the instructions of the vendor.
Cisplatin (in aqueous solution at 1 mg/mL) was purchased from
American Pharmaceutical Products (Schaumburg, Ill) and handled
in subdued light conditions. Adenovirus vectors expressing GFP-
TRAIL–Ad/gTRAIL (titer, 5.3  109 pfu/mL) and GFP vector
control–Ad/GFP (titer, 3.5  109 pfu/mL) were obtained from the
W. M. Keck Center for Cancer Gene Therapy–Vector Core Lab-
oratory at MD Anderson Cancer Center (Houston, Tex). Biotinyl-
ated anti-DR4, anti-DR5, IgG isotype control antibodies, and
strepavidin-phycoerythrin were purchased from R&D Systems
(Minneapolis, Minn) and Becton-Dickinson (Torrance, Calif), re-
spectively, and used for receptor expression analysis. The general
caspase inhibitor Z-VAD-fmk was purchased from R&D Systems.
DAPI (4=,6-diamidino-2-phenylindole), used for nuclear staining,
came from Calbiochem (San Diego, Calif), and thiazolyl blue
tetrazolium bromide came from Sigma-Aldrich (St Louis, Mo).
Receptor Expression Analysis
Cells, seeded 106/well in a 60-mm dish and after overnight
incubation, were treated with cisplatin (2 g/mL) or complete
media for 24 hours. Cells were then trypsinized, washed with
media, and incubated with anti-DR4, anti-DR5, or IgG isotype
antibodies (1 g for 3  105 cells) for 1 hour. Cells were
washed and incubated with strepavidin-phycoerythrin for 30
minutes in the dark and submitted for flow cytometric analysis.
Flow Cytometric Analysis of GFP and GFP-TRAIL
Expression
Cells, seeded at 105/well in 12-well plates and after an overnight
incubation, were either treated with cisplatin (1-2 g/mL) or
complete media (control cells) for 24 hours. Control or cisplatin-
treated cells were infected with 6 or 12 pfu/cell of either Ad/GFP
or Ad/gTRAIL, respectively. The caspase inhibitor Z-VAD-fmk
(60 mol/L) was used to prevent caspase-mediated apoptosis of
Ad/gTRAIL-infected cells, particularly of those pretreated with
cisplatin. Cells were trypsinized, washed with fresh media 48
hours after adenovirus infection, and submitted for analysis of GFP
expression (which correlates with TRAIL expression for Ad/
gTRAIL) by means of flow cytometry. Imaging of cells for GFP
expression was done 24 to 48 hours after Ad/gTRAIL or Ad/GFP
infection by using fluorescence microscopy.
Ad/gTRAIL-mediated Cytotoxicity
Cells were seeded at 104 cells/well in flat-bottom 96-well plates.
After an overnight incubation, they were either incubated with
normal media or with cisplatin (0.5, 1, and 2 g/mL) for 24 hours.
Cells were subsequently infected with Ad/gTRAIL (0, 3, 6, 12, 25,
and 50 pfu/cell) or Ad/GFP (50 pfu/cell). Cell viability at 60 hours
after adenovirus treatment was quantitated by using the thiazolyl
mber 2004
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cisplatin/Ad/gTRAIL treatments was expressed as a percentage of
cell viability of the appropriate controls (those with or without
cisplatin exposure that were not infected with Ad/gTRAIL to
normalize for the mild growth-inhibitory effect of cisplatin pre-
treatment).
Evaluation of Apoptosis
Cells were plated at 105 cells/well in 12-well plates. After an
overnight incubation, they were treated with complete media or
cisplatin (1 g/mL) for 24 hours and then infected with Ad/
gTRAIL (12-25 pfu/cell). Cells were harvested 24 or 48 hours after
adenovirus infection and assayed for apoptosis-induced DNA frag-
mentation resulting in measurable oligonucleosome cytoplasmic
release by using the Cell Death Detection ELISA kit (Roche,
Indianapolis, Ind). The standard fluorescein isothiocyanate–
dependent apoptosis assay techniques (TUNEL or Annexin V)
could not be used in this study because Ad/gTRAIL-infected
cells express GFP, which interferes with fluorescein isothiocya-
nate detection by means of flow cytometry. Apoptosis-induced
DNA fragmentation was also visualized in cells treated with
cisplatin plus Ad/GFP or Ad/gTRAIL combinations by means
Figure 1. Flow cytometric analysis of DR4 and DR5 exp
Exposure of these cells to cisplatin for 24 hours did not
data from 3 independent experiments with similar resof DAPI staining and fluorescence microscopy.
The Journal of ThoraciResults
DR4/DR5 Expression in Thoracic Malignancies
All cultured cancer cell lines evaluated abundantly ex-
pressed DR4, DR5, or both, as determined by means of
indirect immunofluorescent staining and flow cytometry.
Cisplatin (2 g/mL  24 hours) treatment did not alter the
baseline DR4 or DR5 expression of any of the cultured
cancer cells. Representative data are shown for H513
(MPM), H322 (NSCLC), and TE12 (EsC) cells (Figure 1).
Similarly, primary normal cells also expressed these 2
TRAIL receptors, and their levels also did not change with
cisplatin exposure (data not shown).
Cisplatin-mediated Enhancement of GFP-TRAIL
Expression
Baseline expression of GFP-TRAIL fusion protein after
Ad/gTRAIL infection was dependent on the individual cell
line. Significant GFP-TRAIL expression was noted in H513
and H28 cells, whereas it was barely detectable in other cell
lines (Figure 2, A). Titration experiments performed for all
ion on the cultured cancer cells TE12, H322, and H513.
ct the levels of DR4 or DR5 expression. Representative
re shown.ress
affecancer cell lines indicated a cell line–dependent correlation
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viral dose (data not shown). Treating cultured cancer cells
with a nontoxic concentration of cisplatin (1 g/mL) for 24
hours before Ad/gTRAIL infection significantly enhanced
Figure 2. A, Expression of GFP-TRAIL after Ad/gTRAIL i
fluorescence intensity index (GFP mean fluorescence
ground fluorescence) in cultured cancer cells and p
mediated GFP-TRAIL expression in cultured cancer cell
seen by treating cells with cisplatin (1 g/mL) for 24 hou
with a GFP filter setting of H322 cells treated with con
Ad/gTRAIL.the GFP-TRAIL transgene expression, with the increase of
886 The Journal of Thoracic and Cardiovascular Surgery ● Decethe GFP fluorescence intensity ranging from 2-fold (H322)
to 12-fold (TE2). It appeared that cell lines with low base-
line expression of GFP-TRAIL (TE2, TE12, and H2373)
had the highest degrees of gene upregulation versus cell
ion (12 pfu/cell), as measured on the basis of the green
sity of Ad/gTRAIL-infected cells normalized for back-
ry normal cells. Significantly enhanced adenovirus-
, to a much lesser degree, in primary normal cells was
fore Ad/gTRAIL infection. B, Fluorescence microscopy





trol mlines that had higher baseline expression of the transgene (as
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vein endothelial cells showed a very low level of GFP-
TRAIL expression after Ad/gTRAIL infection, as expected
because of the tumor-selective nature of this vector. Pre-
treating normal cells with cisplatin caused slight enhance-
ment of their GFP fluorescence intensity. Cisplatin-mediated
upregulation of GFP-TRAIL expression was readily visualized
Figure 3. A, Cisplatin-mediated enhancement of Ad/gT
viable cells were calculated after normalization for th
are expressed as means  SEM of 4 independent expe
P values to compare the highest doses of Ad/gTRAIL w
and P values of less than .001 for the remaining cell li
of Ad/gTRAIL that mediated a 50% reduction of cell v
curves.by mean of fluorescence microscopy (Figure 2, B).
The Journal of ThoraciCisplatin-mediated Enhancement of Ad/gTRAIL
Cytotoxicity and Apoptosis
Ad/gTRAIL infection of up to 50 pfu/cell exerted little
cytotoxicity in all cell lines. Treating cultured cancer cells
with subtherapeutic doses of cisplatin (0.5-2 g/mL) for 24
hours profoundly enhanced the Ad/gTRAIL cytotoxic effect
(Figure 3, A). The Ad/gTRAIL IC50 values (the multiplicity
cytotoxicity in cultured cancer cells. Percentages of
ld growth-inhibitory effect of cisplatin exposure. Data
nts. By using an unpaired t test evaluating for 2-tailed
r without cisplatin, we had P values of .0167 for H28,
B, Ad/gTRAIL IC50 values (the multiplicity of infection
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spective dose-response curves of cells treated with cisplatin
plus Ad/gTRAIL. They showed significant decreases in a
cisplatin dose-dependent manner (Figure 3, B). This reduc-
tion in IC50 values of Ad/gTRAIL is an indicator of en-
hanced cellular sensitivity to this TRAIL-expressing virus
and resulted in an IC50 value range of 4 pfu/cell (TE2) to 42
pfu/cell (H2373) compared with the IC50 values of cells
treated with Ad/gTRAIL alone (500 pfu/cell in all cell
lines). We treated the same panel of cancer cells with the
vector control virus Ad/GFP at comparable multiplicities of
infection with or without cisplatin pretreatment and did not
see any cytotoxic effects (data not shown).
Apoptosis of cells treated with cisplatin, Ad/gTRAIL, or
the combination of cisplatin followed by Ad/gTRAIL was
quantitated by using the DNA fragmentation assay (Figure
4, A). The magnitude of increase in DNA fragmentation
after treatment was indicated by the fold increase in oligo-
nucleosome cytoplasmic release over the levels of untreated
controls. Although cisplatin alone or Ad/gTRAIL alone
mediated less than a 3-fold increase of DNA fragmentation,
the cisplatin plus Ad/gTRAIL combination induced 4.5-fold
to 5-fold increases in apoptosis. Moreover, propidium io-
dide (PI) staining was also used to evaluate cell viability
after treatment. TE2 cells treated with either cisplatin (1
g/mL) or Ad/gTRAIL (12 pfu/cell) were 9% and 17% PI
positive, respectively, and treating them with the cisplatin
plus Ad/gTRAIL combination caused massive cell death,
with almost 60% of the cells being PI positive (data not
shown). Cells were also stained with DAPI dye to visualize
nuclei undergoing apoptosis after combination treatment.
We were able to confirm the lack of toxicity seen with
Figure 4. Enhancement of apoptosis of cultured canc
combinations measured by means of cell-death ELISA
similar results are shown.cisplatin alone or cisplatin plus Ad/GFP and visualize the
888 The Journal of Thoracic and Cardiovascular Surgery ● Decesignificant apoptosis seen with cisplatin plus Ad/gTRAIL in
representative histologies (data not shown).
Tumor Selectivity of the Ad/gTRAIL
Primary human normal cells (dermal fibroblasts are shown)
were similarly infected by the adenoviral GFP control vec-
tor, showing strong green fluorescence (Figure 5, A). On the
other hand, robust expression of GFP-TRAIL after Adv/
gTRAIL infection was only observed in cancer cells and not
in normal cells, indicating that the differential expression of
the adenoviral transgene is mediated by the tumor-selective
promoter system and not influenced by cellular susceptibil-
ity to virus infection. More importantly, all primary normal
cells were totally refractory to the cytotoxic effect of Ad/
gTRAIL and the cisplatin plus Ad/gTRAIL combination
(Figure 5, B).
Discussion
The development of novel molecularly targeted therapies for
cancer on the basis of the current understanding and new
therapeutic paradigms for this deadly disease are actively being
pursued to supplement or even potentially replace current
ineffective therapies. Activation of receptor-mediated apopto-
sis pathways with their natural ligands in the form of recom-
binant proteins is an attractive therapeutic strategy for receptor-
positive cancer cells. TRAIL has received a great deal of
interest because, in contrast to another member of the TNF
superfamily, Fas ligand, it induces apoptosis in cancer cells but
not in normal cells. Recombinant human TRAIL, produced as
a zinc-containing homotrimer,13 has been shown to be safe in
a preclinical study of nonhuman primates14 and is slated to be
lls treated with sequential cisplatin plus Ad/gTRAIL
presentative data of 3 independent experiments wither ce
. Reused as a systemic therapeutic agent. Investigators are still
mber 2004
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jects.9
On the other hand, the gene encoding TRAIL can be di-
rectly delivered to tumors by an adenovirus vector to provide
high local concentrations of this ligand. Although an excellent
vector for efficient gene delivery, adenovirus infects both nor-
mal and malignant cells, thus posing a real threat of vector
toxicity. Such problems can be minimized by using the hTERT
promoter, which is only active in transformed cells and not in
normal cells.15 In our study we showed the difference between
promoter systems because our GFP vector adenovirus uses the
constitutively active CMV promoter. This is nonspecific be-
cause it is expressed in all cell lines, resulting in similar GFP
expression in both cancer cells and normal cells. Fortunately,
the Ad/gTRAIL’s hTERT-based promoter limits this panex-
Figure 5. A, Fluorescent microscopy of cultured cance
or Ad/gTRAIL. Normal cells were as efficient as cancer
but had decreased GFP-TRAIL expression. B, Absen
Ad/gTRAIL with or without cisplatin pretreatment.
experiments. HUVEC, Human umbilical vein endotheliapression. However, a possible drawback is that it does depend
The Journal of Thoracion the level of hTERT activity in individual cancer cell lines.
The potentially weak transcriptional activity of this tumor-
specific promoter associated with the minimal expression of
the functional gene might adversely affect the therapeutic
utility of such a delivery system. For this reason, we sought to
enhance the GFP-TRAIL expression.
Cisplatin pretreatment did not change the tumor selec-
tivity of Ad/gTRAIL. In fact, as seen in a previously re-
ported study,12 pretreating cancer cells with subtherapeutic
doses of cisplatin before adenoviral infection results in a
significant enhancement of transgene expression. The un-
derlying molecular mechanism of this phenomenon has not
been clearly elucidated. Increased expression of the cox-
sackievirus and adenovirus receptor by the histone deacety-
lase inhibitor depsipeptide has been reported.16 It is not
ls (H322) and human fibroblasts infected with Ad/GFP
in expressing GFP after Ad/GFP infection (25 pfu/cell)
f cytotoxicity in primary normal cells by means of
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ducted to address this possibility. It is conceivable that
cisplatin-mediated sublethal DNA damage might activate
DNA repair and replication machinery that contributes to
the enhanced expression of the adenovirally delivered
genes. The magnitude of enhancement of GFP-TRAIL ex-
pression was greater in the cells with lower baseline gene
expression. This increase in GFP-TRAIL expression in
cisplatin-treated cells was likely partially responsible for
the profound induction of cytotoxicity and apoptosis in
cancer cells that spared normal cells.
The enhanced expression of GFP-TRAIL is not the only
benefit of cisplatin pretreatment. Cisplatin has been shown
to sensitize TRAIL-resistant cells to the soluble form of this
death-inducing ligand.8,17 We have found this sensitization
effect to have at least a 48-hour window after removal of
cisplatin (data not shown). We believe that this sensitization
to TRAIL’s effects is another method, as important as the
increase in adenoviral transgene expression, by which cis-
platin enhances the cytotoxic effect of the Ad/gTRAIL on
cancer cells. In other words, cisplatin pretreatment, in ad-
dition to its ability to increase TRAIL expression on effector
cells, also might enhance the responsiveness of target cells
whose DR4-DR5 receptors engage membrane-bound
TRAIL on the neighboring cells in a paracrine bystander
fashion. The relative contribution of each mechanism to the
synergistic cytotoxic interaction of the cisplatin plus Ad/
gTRAIL combination is not clear and is certainly difficult to
dissect. It is likely cell line dependent as to which mecha-
nism plays the most important role in enhancement.
It is conceivable, however, that adenovirus gene therapy
is most suitable for local or regional application. Cisplatin-
mediated enhancement of the cytotoxic efficacy of Ad/
gTRAIL on cancer cells, while sparing normal cells, tre-
mendously widens the therapeutic index of such a treatment
strategy. Functionally speaking, cisplatin can be viewed as
a sensitizer of TRAIL and vice versa. It is reasonable to
envision use of Ad/gTRAIL for local or regional delivery to
bulky cancers in conjunction with systemic cisplatin-based
chemotherapy for optimal and synergistic antitumor effects.
In vivo experiments with nude mice bearing human xe-
nogafts are being performed to further evaluate this potent
combination.
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Discussion
Dr Jack Roth (Houston, Tex). One interesting aspect, as you
pointed out, is TRAIL resistance. I wondered whether you looked
at these cell lines with TRAIL protein to see whether you get the
same effect in combination with cisplatin, or does the use of this
adenovirus construct allow you to overcome TRAIL resistance in
resistant cell lines?
Dr Reddy. We did look at the soluble and recombinant forms
of TRAIL in combination with cisplatin and saw that we were able
to sensitize resistant cell lines to the recombinant soluble TRAIL
form using cisplatin pretreatment. That combination was also
found to be safe in normal cells at doses of up to 100 ng/mL
soluble TRAIL. We did not observe the ability of the adenovirus
construct to overcome recombinant TRAIL resistance.
Dr Roth. Was the magnitude of the effect the same that you
saw with the adenovirus TRAIL?
mber 2004
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cancer cell lines, the TE2s, TE12s, and TE3s, only 2 of which I
have replicated here. I believe that we saw similar effects, but I
cannot attest to the mesotheliomas or the NSCLC lines.
Dr Roth. One final question. Is this a completely schedule-
dependent effect? In other words, if you treat simultaneously with
the cisplatin and your adenovirus TRAIL construct, do you see this
synergistic interaction, or if you treat with the cisplatin afterward?
Dr Reddy. We are currently working on the specific pharma-
cokinetics of what would be the ideal treatment schedule. With
concurrent treatment, we do not see this enhancement. We are
trying to evaluate whether we need the full 24 hours of pretreat-
ment or whether we can pretreat for only 8 hours. Our goal is to
eventually mimic what would be done in a clinical setting.
Dr Roth. And could you just speculate on the mechanism here?
Do you think this is an enhancement of adenoviral transduction, or
is there some other pathway that is activated by the cisplatin that
causes the enhanced TRAIL responsiveness?
Dr Reddy. Specifically for cisplatin, our hypothesis is that the
enhanced transduction might be due to the DNA-alkylating effect
of the cisplatin itself, causing an increase in the DNA repair
machinery of the cell, thus increasing the adenovirus gene expres-
sion. Other groups have looked at using histone deacetylase inhib-
itors as a method of enhancing adenoviral gene expression and
have shown an increase in CAR, the Coxsackie virus and adeno-
virus receptor, expression. For cisplatin though, we think it is
related to the DNA repair machinery, but we have not evaluated
the CAR expression yet.
Dr Nguyen. I am really honored to have Dr Roth open the
discussion of this article because the idea of using cisplatin in
The Journal of Thoracicombination with adenovirus expression was actually coming from
Dr Roth’s laboratory when I was his fellow.
Dr Roth, that is a very important question, the third one,
concerning the potential mechanisms of this combination. We
thought hard about it, and we tried to find a way to dissect out the
molecular mechanism. We believe that the increased expression of
TRAIL is one mechanism. The other mechanism that we think is
happening is that somehow cisplatin enhances the responsiveness
of the target cells. Therefore we have 2 populations. One popula-
tion is cells that infect the virus. The other population is cells that
are actually going to be affected by the TRAIL itself. Therefore I
think that the cisplatin would do both, and we tried to find a way
to dissect it out. Dr Roth touched on a very important fundamental
question to this combination.
Dr David R. Jones (Charlottesville, Va). Just to follow up on
that, have you looked at any other sensitizing chemotherapy agents
at all? And how long does this effect last? The assays you showed
were a more short-term kind of apoptotic assay. Do you really
know how many cells die after 7 days of treatment?
Dr Reddy. We have looked at other chemosensitizers. We have
looked at trichostatin A in combination with the adenovirus
TRAIL, and we are still evaluating that. We have also looked at
trichostatin A, which is a histone deacetylase inhibitor, in combi-
nation with a recombinant protein soluble TRAIL and seen a
significant enhancement there. Therefore I think there are other
noncisplatin chemoenhancers that we can use.
In terms of the length of our treatment, most of these were, I
think, a total of about 4 to 5 days, even in our apoptosis assays. We
have not looked at anything as far out as 7 days, but clearly we
have seen a synergistic effect with the combination, even in that
short period of time.
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